Clinical trial
A study to evaluate the long-term safety of astegolimab in participants with chronic obstructive pulmonary disease (COPD)
A study to evaluate the long-term safety of astegolimab in participants with chronic obstructive pulmonary disease (COPD)
ClinicalTrials.gov ID: NCT05878769
Sponsor: Hoffmann-La Roche
Information provided by: Hoffmann-La Roche (Responsible Party)
Last Update Posted: 2024-06-07
Brief Summary:
The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.
Official Title:
A Phase III Open-Label Extension Study to Evaluate the Long-Term Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease
Intervention / Treatment:
- Drug: Astegolimab
| Category | Value |
|---|---|
| Study Start (Actual) |
2023-06-28
|
| Primary Completion (Estimated) |
2027-06-30
|
| Study Completion (Estimated) |
2027-06-30
|
| Enrollment (Estimated) | 2000 |
| Study Type | Interventional |
| Phase | Phase 3 |
| Other Study ID Numbers |
GB43374
|